Prazma CM - Search Results

1

Eosinophils in Health and Disease: A State-of-the-Art Review.

Wechsler ME, Munitz A, Ackerman SJ, Drake MG, Jackson DJ, Wardlaw AJ, Dougan SK, Berdnikovs S, Schleich F, Matucci A, Chanez P, Prazma CM, Howarth P, Weller PF, Merkel PA. Wechsler ME, et al. Among authors: prazma cm. Mayo Clin Proc. 2021 Oct;96(10):2694-2707. doi: 10.1016/j.mayocp.2021.04.025. Epub 2021 Sep 15. Mayo Clin Proc. 2021. PMID: 34538424 Free article. Review.

2

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.

Pavord ID, Buhl R, Kraft M, Prazma CM, Price RG, Howarth PH, Yancey SW. Pavord ID, et al. Among authors: prazma cm. ERJ Open Res. 2022 May 3;8(2):00560-2021. doi: 10.1183/23120541.00560-2021. eCollection 2022 Apr. ERJ Open Res. 2022. PMID: 35509441 Free PMC article.

3

Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma.

Korn S, Howarth P, Smith SG, Price RG, Yancey SW, Prazma CM, Bel EH. Korn S, et al. Among authors: prazma cm. Respir Res. 2022 Mar 4;23(1):45. doi: 10.1186/s12931-022-01959-1. Respir Res. 2022. PMID: 35246123 Free PMC article. Clinical Trial.

4

Rigor Is Needed When Making Comparative Analyses of Biologics in Severe Asthma.

Prazma CM, Katial R, Howarth P, Bradford E, Martin N, Pizzichini E. Prazma CM, et al. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1508-1510. doi: 10.1164/rccm.201712-2455LE. Am J Respir Crit Care Med. 2018. PMID: 29360390 No abstract available.

5

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Bel EH, et al. Among authors: prazma cm. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25199060 Free article. Clinical Trial.

6

Association of depressive symptoms with health status and markers of uncontrolled severe asthma.

Khurana S, Lyness JM, Mallett S, Nelsen LM, Prazma CM, Albers FC, Forshag M, Llanos JP, Yancey SW, Ortega HG. Khurana S, et al. Among authors: prazma cm. Allergy Asthma Proc. 2019 Jul 1;40(4):230-239. doi: 10.2500/aap.2019.40.4229. Allergy Asthma Proc. 2019. PMID: 31262378 Clinical Trial.

7

Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.

Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, Prazma CM, Ortega H, Martin JG, Nair P. Sehmi R, et al. Among authors: prazma cm. Clin Exp Allergy. 2016 Jun;46(6):793-802. doi: 10.1111/cea.12695. Clin Exp Allergy. 2016. PMID: 26685004

8

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use.

Albers FC, Hozawa S, Bratton DJ, Yancey SW, Prazma CM, Humbert M, Liu MC. Albers FC, et al. Among authors: prazma cm. Allergy. 2020 Apr;75(4):942-946. doi: 10.1111/all.14048. Epub 2019 Oct 2. Allergy. 2020. PMID: 31520471 Free PMC article. No abstract available.

9

Characterisation of an OCS-dependent severe asthma population treated with mepolizumab.

Prazma CM, Wenzel S, Barnes N, Douglass JA, Hartley BF, Ortega H. Prazma CM, et al. Thorax. 2014 Dec;69(12):1141-2. doi: 10.1136/thoraxjnl-2014-205581. Epub 2014 May 16. Thorax. 2014. PMID: 24834924 Clinical Trial.

10

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.

Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H. Magnan A, et al. Among authors: prazma cm. Allergy. 2016 Sep;71(9):1335-44. doi: 10.1111/all.12914. Epub 2016 May 24. Allergy. 2016. PMID: 27087007 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page